Resumen

PADULLES ZAMORA, Núria et al. Retrospective analysis of omalizumab in patients with severe allergic asthma. Farm Hosp. [online]. 2013, vol.37, n.5, pp.399-405. ISSN 2171-8695.  https://dx.doi.org/10.7399/FH.2013.37.5.728.

Objective: To assess the efficacy and safety profile of omalizumab treatment. The conditions under which omalizumab was prescribed agreed with those in Xolair^® drug information: age > 12 years old, severe uncontrolled asthma, FEV, < 80%, IgE 30-700 UI/ml and positive test results for perennial allergens. Methods: Asthmatic patients treated with omalizumab between January 2010 and July 2011 were evaluated retrospectively. Age, sex, weight, IgE level, concomitant asthma medications, change in FEV₁, emergency department visits, hospitalizations, asthma exacerbations and corticosteroids bursts were recorded before and after omalizumab initiation. A 1.5-year period was chosen. Results: A total of 22 patients were included. The mean weight of subjects was 73 Kg (range, 51-102). Mean IgE was 203 UI/ml (range, 30-992) and mean FEV₁ 60% (range, 30-93%) at baseline. Adverse events were observed in 4 patients. There were no significant changes in FEV₁ values after omalizumab treatment but omalizumab was associated with a reduction in concomitant asthma medications use in 14 patients and improvements in global asthma control in 12. Conclusion: In these patients add-on therapy with omalizumab reduced asthma exacerbations and emergency visits or hospitalizations. Only 55% of patients significantly improved global asthma control and no significant changes in FEV₁, were observed.mejoría global según criterios clínicos y no se observaron cambios estadísticamente significativos en la FEV₁.

Palabras clave : Severe persistent asthma; omalizumab; efficacy; safety.

        · resumen en Español     · texto en Español     · Español ( pdf )